Antigen Presentation by MHC Class II was found to be the most relevant biological pathway in our study, which is in line with findings of Wilson et al (2006), who demonstrated that a cluster of AML patients with high WT1 expression also showed low expression of MHC‐II genes. The gene discussed is WT1; the disease is acute myeloid leukemia.